کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
2138516 | 1087878 | 2007 | 4 صفحه PDF | دانلود رایگان |
عنوان انگلیسی مقاله ISI
Bortezomib is an effective agent for MDS/MPD syndrome with 5qâ anomaly and thrombocytosis
دانلود مقاله + سفارش ترجمه
دانلود مقاله ISI انگلیسی
رایگان برای ایرانیان
کلمات کلیدی
موضوعات مرتبط
علوم زیستی و بیوفناوری
بیوشیمی، ژنتیک و زیست شناسی مولکولی
تحقیقات سرطان
پیش نمایش صفحه اول مقاله
![عکس صفحه اول مقاله: Bortezomib is an effective agent for MDS/MPD syndrome with 5qâ anomaly and thrombocytosis Bortezomib is an effective agent for MDS/MPD syndrome with 5qâ anomaly and thrombocytosis](/preview/png/2138516.png)
چکیده انگلیسی
Thrombocytosis is not a frequent event in myelodysplasia (MDS) and is observed mainly in 5qâ syndrome and MDS/myeloproliferative (MPD) overlap syndromes. The pathogenetic mechanism of thrombocytosis in 5qâ has not been fully elucidated to-date. Bortezomib is a proteasome inhibitor which seems to be effective in MDS. We present here the first case in the literature with MDS/MPD syndrome, sole 5qâ anomaly and thrombocytosis in which bortezomib administration normalized platelet count, produced a major erythroid response, and reduced levels of interleukin-6 (IL-6) and TNF-α while increased levels of IL-4 in the bone marrow plasma. The study of such cases will reveal the exact role of bortezomib in the management of MDS/MPD.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Leukemia Research - Volume 31, Issue 4, April 2007, Pages 559-562
Journal: Leukemia Research - Volume 31, Issue 4, April 2007, Pages 559-562
نویسندگان
Evangelos Terpos, Evgenia Verrou, Anastasia Banti, Vassiliki Kaloutsi, Anna Lazaridou, Kostas Zervas,